Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
16.52
Dollar change
+0.73
Percentage change
4.62
%
IndexRUT P/E- EPS (ttm)-2.36 Insider Own32.57% Shs Outstand87.23M Perf Week9.69%
Market Cap1.44B Forward P/E- EPS next Y-1.91 Insider Trans5.13% Shs Float58.93M Perf Month-1.84%
Income-188.92M PEG- EPS next Q-0.65 Inst Own76.20% Short Float16.31% Perf Quarter9.26%
Sales0.00M P/S- EPS this Y-8.14% Inst Trans2.05% Short Ratio16.28 Perf Half Y32.05%
Book/sh3.97 P/B4.16 EPS next Y25.32% ROA-52.11% Short Interest9.61M Perf Year29.16%
Cash/sh4.19 P/C3.94 EPS next 5Y- ROE-55.68% 52W Range9.67 - 17.85 Perf YTD13.15%
Dividend Est.- P/FCF- EPS past 5Y-84.59% ROI-54.52% 52W High-7.45% Beta-1.49
Dividend TTM- Quick Ratio12.72 Sales past 5Y0.00% Gross Margin- 52W Low70.84% ATR (14)0.83
Dividend Ex-Date- Current Ratio12.72 EPS Y/Y TTM-9.65% Oper. Margin0.00% RSI (14)60.45 Volatility5.53% 5.65%
Employees155 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.55 Target Price35.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-14.45% Payout- Rel Volume1.32 Prev Close15.79
Sales Surprise- EPS Surprise-9.68% Sales Q/Q- EarningsFeb 26 AMC Avg Volume590.16K Price16.52
SMA207.51% SMA509.55% SMA20024.16% Trades Volume778,236 Change4.62%
Date Action Analyst Rating Change Price Target Change
Apr-25-23Downgrade BofA Securities Buy → Underperform $34 → $9
Feb-08-23Initiated CapitalOne Overweight $40
Feb-03-23Initiated Oppenheimer Perform
Dec-15-22Initiated H.C. Wainwright Buy $35
Dec-14-22Initiated Needham Buy $40
Dec-05-22Initiated Goldman Buy $45
Dec-01-22Initiated BofA Securities Buy $34
Mar-13-24 07:07AM
Feb-28-24 04:32AM
Feb-26-24 04:30PM
Jan-31-24 05:12PM
Jan-17-24 08:00AM
08:00AM Loading…
Dec-19-23 08:00AM
Nov-27-23 10:00AM
Nov-17-23 07:00AM
Nov-14-23 08:00AM
Nov-06-23 05:16PM
04:30PM
Nov-04-23 12:16PM
Oct-30-23 07:27PM
08:00AM
Oct-23-23 01:20PM
10:20AM Loading…
Oct-20-23 10:20AM
Sep-29-23 12:43PM
Sep-11-23 09:02PM
Aug-16-23 08:00AM
Aug-10-23 02:28PM
Aug-07-23 04:30PM
Jun-17-23 08:29AM
Jun-12-23 08:00AM
Jun-08-23 12:38PM
07:00AM
Jun-06-23 10:31PM
04:01PM
Jun-05-23 04:06PM
12:30PM
Jun-04-23 12:45PM
08:00AM Loading…
May-30-23 08:00AM
May-25-23 08:30PM
05:00PM
May-01-23 09:00AM
Apr-30-23 09:57AM
Apr-26-23 09:31AM
Apr-21-23 01:02PM
11:44AM
Apr-12-23 08:00AM
Mar-21-23 05:30AM
Mar-06-23 04:30PM
Feb-27-23 08:00AM
Feb-15-23 10:24AM
Jan-09-23 08:57AM
08:30AM
Jan-08-23 05:00PM
Jan-03-23 01:04AM
01:00AM
Dec-20-22 08:00AM
Dec-14-22 01:02PM
Dec-05-22 09:05AM
Nov-21-22 08:33AM
Nov-17-22 07:00AM
Nov-11-22 07:00AM
Nov-07-22 04:30PM
Oct-17-22 08:00AM
Sep-12-22 08:30AM
Aug-09-22 08:50AM
Aug-04-22 04:30PM
Aug-02-22 08:00AM
Jul-29-22 11:33AM
Jul-18-22 09:55AM
Jun-30-22 01:08PM
Jun-23-22 07:26PM
Jun-21-22 08:30AM
Jun-15-22 02:45PM
05:41AM
Jun-14-22 08:00PM
05:42PM
05:34PM
09:05AM
07:30AM
Jun-13-22 04:17PM
07:56AM
Jun-12-22 05:00PM
May-23-22 08:30AM
May-12-22 04:30PM
May-10-22 04:26PM
Apr-06-22 08:30AM
Mar-07-22 07:30AM
Feb-28-22 04:05PM
Jan-24-22 04:51AM
Jan-05-22 08:00AM
Dec-27-21 10:49AM
Nov-25-21 04:55AM
Nov-22-21 07:00AM
Nov-18-21 08:00AM
Nov-08-21 04:50PM
Nov-03-21 08:00AM
Oct-20-21 09:35AM
Sep-13-21 07:00AM
Aug-27-21 07:08AM
Aug-17-21 07:00AM
Aug-10-21 04:05PM
Aug-04-21 08:00AM
Jul-27-21 07:00AM
Jun-28-21 04:18PM
Jun-21-21 09:29AM
07:00AM
Jun-01-21 04:01PM
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blackman Samuel C.HEAD OF R&DMar 25 '24Sale16.0110,000160,0551,184,662Mar 26 06:09 PM
Blackman Samuel C.HEAD OF R&DMar 11 '24Sale15.2430,000457,3141,194,662Mar 13 04:24 PM
Blackman Samuel C.HEAD OF R&DFeb 27 '24Sale16.1120,000322,1661,224,662Feb 28 07:55 PM
Bender JeremyCHIEF EXECUTIVE OFFICERFeb 16 '24Sale15.257,615116,114721,813Feb 20 06:14 PM
Dubow AdamGENERAL COUNSELFeb 16 '24Sale15.253,24249,43416,585Feb 20 06:48 PM
York Charles N IICOO, CFO AND SECRETARYFeb 16 '24Sale15.252,66640,651277,754Feb 20 06:36 PM
Blackman Samuel C.HEAD OF RESEARCH AND DEVELOPMEFeb 16 '24Sale15.252,25834,4301,244,662Feb 20 06:26 PM
Dubow AdamGeneral CounselNov 16 '23Sale11.695,31362,10911,428Nov 17 06:30 PM
Bender JeremyChief Executive OfficerNov 16 '23Sale11.693,10736,321709,429Nov 17 06:20 PM
York Charles N IICOO, CFO and SecretaryNov 16 '23Sale11.6995611,176270,170Nov 17 06:33 PM
Blackman Samuel C.Head of Research and DevelopmeNov 16 '23Sale11.697098,2881,238,234Nov 17 06:26 PM
AI Day1 LLC10% OwnerOct 20 '23Buy9.97111,3871,110,90712,929,322Oct 20 04:02 PM
AI Day1 LLC10% OwnerOct 19 '23Buy10.06384,4003,867,37212,817,935Oct 20 04:02 PM
AI Day1 LLC10% OwnerOct 18 '23Buy10.21979,66710,000,04912,433,535Oct 20 04:02 PM
Bender JeremyChief Executive OfficerAug 17 '23Sale13.862,99641,525704,224Aug 17 06:16 PM
York Charles N IICOO, CFO and SecretaryAug 17 '23Sale13.8692212,779267,501Aug 17 07:02 PM
Blackman Samuel C.Head of Research and DevelopmeAug 17 '23Sale13.866689,2581,236,319Aug 17 06:21 PM
AI Day1 LLC10% OwnerJun 09 '23Buy13.00769,2309,999,99011,453,868Jun 12 04:03 PM
Blackman Samuel C.Chief Medical OfficerJun 05 '23Sale16.001,22919,6641,234,363Jun 07 04:51 PM
Bender JeremyChief Executive OfficerMay 16 '23Sale13.123,10440,7321,179,484May 17 06:27 PM
York Charles N IICOO, CFO and SecretaryMay 16 '23Sale13.1295512,532264,798May 17 06:36 PM
Blackman Samuel C.Chief Medical OfficerMay 16 '23Sale13.126929,0811,235,592May 17 06:31 PM